Results 81 to 90 of about 8,428 (249)

The Polyphosphate Kinase of Escherichia coli Is Required for Full Production of the Genotoxin Colibactin

open access: yesmSphere, 2020
Colibactin induces DNA damage in mammalian cells and has been linked to the virulence of Escherichia coli and the promotion of colorectal cancer (CRC). By looking for mutants attenuated in the promoter activity of clbB encoding one of the key enzymes for
Min Tang-Fichaux   +5 more
doaj   +1 more source

Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability

open access: yesArthritis &Rheumatology, Volume 78, Issue 4, Page 976-984, April 2026.
Objective We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011–2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman   +6 more
wiley   +1 more source

Mesalamine-induced myopericarditis - A case report

open access: yesRevista Española de Enfermedades Digestivas, 2016
Myopericarditis has occasionally been reported as a side effect of mesalamine in patients with inflammatory bowel disease. We present a 20-year-old woman with ulcerative colitis admitted with chest pain. After thorough investigation she was diagnosed with myopericarditis potentially related to mesalamine.
Bernardo,Sónia   +2 more
openaire   +3 more sources

Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach

open access: yes, 2016
George P Christophi, Arvind Rengarajan, Matthew A Ciorba Division of Gastroenterology, Washington University School of Medicine, St.
Christophi GP, Rengarajan A, Ciorba MA
core  

Mesalamine Intolerance in Three Children with Crohn's Disease

open access: yes, 2016
Objective: To present the mesalamine-induced acute exacerbation of symptoms and inflammatory markers in children with Crohn's disease (CD). Clinical Presentation and Intervention: Three children who presented with CD had acute exacerbation of colitis ...
Kuloglu, Zarife   +6 more
core   +1 more source

Mesalamine-induced myocarditis following diagnosis of Crohn's disease: A case report

open access: yesRevista Portuguesa de Cardiologia, 2013
Mesalamine is a common treatment for Crohn's disease, and can be rarely associated with myocarditis through a mechanism of drug hypersensitivity. We present the case of a 19-year-old male who developed chest pain two weeks after beginning mesalamine ...
Carlos Galvão Braga   +7 more
doaj   +1 more source

Not Your Typical Ulcerative Colitis Patient [PDF]

open access: yesModern Medicine
Background: Extraintestinal manifestations (EIMs) of inflammatory bowel diseases (IBDs) are a common and debilitating feature of disease, occurring in up to 40% of patients with IBD.
Teodora SPATARU   +3 more
doaj   +1 more source

Once-Daily MMX (R) Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis

open access: yes, 2012
OBJECTIVES: Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse and is the recommended first-line maintenance therapy.
Streck, Paul   +4 more
core   +1 more source

Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial

open access: yes, 2008
Sunanda Kane1, William Holderman2, Peter Jacques2, Todd Miodek31Mayo Clinic College of Medicine, Rochester, MN, USA; 2Digestive Health Specialists, Tacoma, WA, USA; 3University of Chicago, Chicago, IL, USABackground and Aims: Multiple studies have ...
Sunanda Kane   +3 more
core  

RP-HPLC method development and validation for simultaneous estimation of mesalamine and curcumin in bulk form as well as nanostructured lipid carriers

open access: hybrid, 2022
Ankit Awasthi   +16 more
openalex   +1 more source

Home - About - Disclaimer - Privacy